Alcon Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALCON LABS
ALCON LABS has nineteen approved drugs.
There are forty-six US patents protecting ALCON LABS drugs.
There are two hundred and forty-one patent family members on ALCON LABS drugs in thirty-three countries and twenty-nine supplementary protection certificates in eleven countries.
Summary for Alcon Labs
| International Patents: | 241 |
| US Patents: | 46 |
| Tradenames: | 16 |
| Ingredients: | 14 |
| NDAs: | 19 |
Drugs and US Patents for Alcon Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 10,945,948 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | FLUORESCITE | fluorescein sodium | INJECTABLE;INTRAVENOUS | 021980-001 | Mar 28, 2006 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | 10,646,437 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 9,056,057 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | 9,827,191 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 11,028,081 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 8,394,826 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alcon Labs
International Patents for Alcon Labs Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2584858 | ⤷ Start Trial |
| Australia | 2018202074 | ⤷ Start Trial |
| China | 105534970 | ⤷ Start Trial |
| Poland | 2722035 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2010148190 | ⤷ Start Trial |
| Japan | 2022009979 | ⤷ Start Trial |
| Australia | 2020203976 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alcon Labs Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0364417 | 97C0128 | France | ⤷ Start Trial | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 |
| 3053913 | 132020000000043 | Italy | ⤷ Start Trial | PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121 |
| 3053913 | 20C1017 | France | ⤷ Start Trial | PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
| 1631293 | 2014C/042 | Belgium | ⤷ Start Trial | PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221 |
| 3461484 | C202130024 | Spain | ⤷ Start Trial | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107 |
| 3053913 | C202030018 | Spain | ⤷ Start Trial | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119 |
| 3461484 | 301101 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
